Clinical Trials Directory

Trials / Completed

CompletedNCT03541265

Liposomal Bupivacaine in Total Knee Arthroplasty

Efficacy of Regional Adductor Canal Block Using Extended Release Liposomal Bupivacaine in Total Knee Arthroplasty: A Randomized Prospective Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Bronx-Lebanon Hospital Center Health Care System · Academic / Other
Sex
All
Age
25 Years
Healthy volunteers
Not accepted

Summary

Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.

Detailed description

Multimodal pain approach is now an accepted standard of care to improve pain, enable earlier mobilization and faster recovery, decreased length of stay, and reduce opioid consumption and related side effects. The multimodal approach includes peri-operative oral and IV analgesics, local periarticular injections (PAI), and/or regional blocks such as femoral nerve blocks nerve or subsartorial saphenous nerve (adductor canal) blocks. Extended release bupivacaine (Exparel - Pacira Pharmaceuticals, Parsippany, NJ, USA) in liposomal form was developed for longer lasting post-operative analgesia. There are limited studies analyzing its efficacy of single injection liposomal bupivacaine in adductor canal block in total knee arthroplasty. The investigators hypothesized that a single adductor canal regional block injection would provide similar pain relief as peri-articular infiltration of Exparel.

Conditions

Interventions

TypeNameDescription
DRUGExparellong-acting Bupivacaine extended release liposome compound
PROCEDUREAdductor block protocolAdductor block using Exparel
PROCEDUREperi-articular injection protocolperi-articular injection using Exparel

Timeline

Start date
2016-05-01
Primary completion
2017-06-01
Completion
2018-03-01
First posted
2018-05-30
Last updated
2018-05-30

Source: ClinicalTrials.gov record NCT03541265. Inclusion in this directory is not an endorsement.